1. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Issue 12 (December 2018) Authors: Döhner, Hartmut; Dolnik, Anna; Tang, Lin; Seymour, John; Minden, Mark; Stone, Richard; del Castillo, Teresa; Al-Ali, Haifa; Santini, Valeria; Vyas, Paresh; Beach, C.; MacBeth, Kyle; Skikne, Barry; Songer, Steve; Tu, Nora; Bullinger, Lars; Dombret, Hervé Journal: Leukemia Issue: Volume 32:Issue 12(2018) Page Start: 2546 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG-TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML-001 TRIAL OF ORAL AZACITIDINE. (23rd June 2022) Authors: Wei, A. H.; Döhner, H.; Sayar, H.; Ravandi, F.; Montesinos, P.; Dombret, H.; Selleslag, D.; Porkka, K.; Jang, J.-H.; Skikne, B.; Beach, C.; Prebet, T.; Zhang, G.; Risueño, A.; Ugidos Guerrero, M.; See, W. L.; Menezes, D.; Roboz, G. J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P571: ORAL AZACITIDINE VS MIDOSTAURIN AS MAINTENANCE TREATMENT FOR FLT3 MUTANT ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION: AN INDIRECT TREATMENT COMPARISON. (23rd June 2022) Authors: Oliva, E. N.; Chen, C.; Rahim, S. N.; Seuro, B.; Vasconcelos, A.; Gaugler, L.; Skikne, B.; Prebet, T.; Cameron, H.; Beach, C.; Thompson, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 470 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗